Oxidant/antioxidant Parameters and their Relationship with Chemotherapy in Hodgkin's Lymphoma

• Published in: Journal of international medical research Vol. 33; no. 6; pp. 687 - 692
• Main Authors: Kaya, E, Keskin, L, Aydogdu, I, Kuku, I, Bayraktar, N, Erkut, MA
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.11.2005
• Subjects: Adolescent; Adult; Antioxidants - metabolism; Bleomycin - therapeutic use; Catalase - drug effects; Dexamethasone - therapeutic use; Doxorubicin - therapeutic use; Female; Glutathione Peroxidase - drug effects; Hodgkin Disease - drug therapy; Hodgkin Disease - metabolism; Humans; Male; Malondialdehyde - metabolism; Middle Aged; Nitric Oxide - metabolism; Oxidants - blood; Superoxide Dismutase - drug effects; Vincristine - therapeutic use; ABVD; Cancer chemotherapy; Free radicals; Spectrofluorometry; Oxidant; Antioxidant; Spectrophotometry; Cisplatin; Hodgkin's lymphoma
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/147323000503300611

This study investigated changing levels of serum oxidant/antioxidant with chemotherapy and their relation to treatment in 34 Hodgkin's lymphoma patients. The patient population consisted of 19 males and 15 females. Mean age was 30.41 ± 12.08 years. All patients received the adriamycin, bleomycin, vincristine and dexamethasone (ABVD) treatment protocol. Blood samples were taken before treatment, and on days 1 and 7 during treatment for measurement of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), malondialdehyde (MDA), nitric oxide (NO) and enzyme activities. After ABVD treatment, mean free radical levels were increased and antioxidant levels were significantly decreased in the serum. ABVD treatment results in an increase of free radical levels and a decrease of antioxidant levels in the serum of patients with Hodgkin's lymphoma.